Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Hoffmann-La Roche
AIDS groups to pressure big pharma to lower cost of Fuzeon
May 14th, 2003
A coalition of AIDS groups from across California, the U.S., Italy, and other parts of the world launched a campaign urging pharmaceutical maker, F. Hoffmann-La Roche to lower the price of its new anti-HIV drug, Fuzeon, to a level that will make it accessible to all HIV/AIDS patients. In a letter to Roche chairman and CEO Franz B. Humer, the U.S. advocates wrote "Fuzeon's $20,000 price tag is out of the price range for most AIDS patients," and "threatens to bankrupt already financially stressed Medicaid and AIDS drug assistance programs." "Fuzeon must not be priced significantly above existing HIV/AIDS medications," said Michael Weinstein, AIDS...
Source: Biotech Week (2003-05-14)
|
